The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases

Creative Commons License

Turk C., OKAY M., TÜRK S., Temirci E. S., Javad O., AKSU S., ...More

TURKISH JOURNAL OF MEDICAL SCIENCES, vol.49, no.2, pp.661-674, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 49 Issue: 2
  • Publication Date: 2019
  • Doi Number: 10.3906/sag-1807-152
  • Journal Name: TURKISH JOURNAL OF MEDICAL SCIENCES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.661-674
  • Keywords: Lymphoma, ruxolitinib, JAK/STAT signaling pathway, B-CELL LYMPHOMA, CD30 EXPRESSION, RETROSPECTIVE ANALYSIS, CD20, PATHOGENESIS, PROGNOSIS, RITUXIMAB, PATHWAY
  • Hacettepe University Affiliated: Yes

Abstract

Background/aim: Ruxolitinib, a JAK/STAT signaling pathway inhibitor targeted drug, has been approved for the controlling of disease symptoms and splenomegaly in patients with myeloproliferative neoplastic diseases. Recently, it has been proposed that ruxolitinib-induced JAK/STAT pathway inhibition in myelofibrosis is associated with an elevated frequency of aggressive B-cell lymphomas. However, the biological basis and significance of this pharmacobiological adverse event is unknown. The aim of this bioinformatics study is to detect any possible confounding effects of ruxolitinib on the genesis of lymphoproliferative disorders.